このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

睡眠時随伴症の非薬物療法 (Hypnosomnia)

2026年11月5日 更新者:Chantal Berna Renella

睡眠時随伴症に対する非薬物療法の有効性の評価: ランダム化比較試験

The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis (N=60).

Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.

Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).

  • An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography (EEG). Estimated duration: 2h.
  • A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second EEG will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).

This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.

For the validation of the EEG methodology, healthy volunteers (N=50) will complete a unique visit resembling the initial study visit of patients.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

110

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Canton of Vaud
      • Lausanne、Canton of Vaud、スイス、1005
        • Centre hospitalier universitaire vaudois (CHUV)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Patients with NREM parasomnia (N=60):

Inclusion Criteria:

  • Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
  • Willling and able to give informed consent
  • Reporting at least one parasomniac episode per month
  • Reporting at least one parasomniac episode the month prior

Exclusion Criteria:

  • Refusal to use the home video recording device
  • Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
  • A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) >= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)

Healthy volunteers (N=50):

Inclusion Criteria:

- Adult (≥ 18 yo) willing and able to give informed consent.

Exclusion criteria:

  • Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder;
  • Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines);
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia);
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder);
  • Current history of psychiatric or neurological disorders (e.g., migraines).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Medical hypnosis (HYP) (N=30)

3 medical hypnosis interventions

Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)

アクティブコンパレータ:Standard Of Care (SOC) (N=30)

3 standard of care quality and sleep safety interventions

Sleep hygiene and safety education session

介入なし:Healthy volunteers (N=50)

Unique EEG visit resembling the initial study visit of patients with NREM parasomnias

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

Parasomniac episodes scored on infrared home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Duration of parasomniac episodes
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment

Using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
Rate of confusional arousals, sleepwalking and sleep terrors episodes
時間枠:Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment

Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
Incidence of emotions related to parasomniac episodes
時間枠:Through study duration, an average of 9 weeks

Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?)

Through study duration, an average of 9 weeks
Quality of life score
時間枠:At Day 0, Week 11 and Week 18

Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life.

At Day 0, Week 11 and Week 18
Anxiety and depression scores
時間枠:At Day 0 and Week 11

Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score >8 denotes anxiety or depression.

At Day 0 and Week 11
Traumatic events score
時間枠:At Day 0

Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score.

At Day 0
Fatigue score
時間枠:At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score >22 denotes excessive fatigue.

At Week 2, Week 11 and Week 18
Sleepiness score
時間枠:At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness.

At Week 2, Week 11 and Week 18
Sleep quality score
時間枠:At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances.

At Week 2, Week 11 and Week 18
Severity of arousal disorders score
時間枠:At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders.

At Week 2, Week 11 and Week 18
Circadian typology score
時間枠:At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Horne & Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness.

At Week 2, Week 11 and Week 18
Changes in sleep architecture
時間枠:At Day 0 and Week 11

Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®.

At Day 0 and Week 11
Sleep eye movements
時間枠:At Week 11 (optional)

Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep muscles activity
時間枠:At Week 11 (optional)

Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1®

At Week 11 (optional)
Sleep cardiac activity
時間枠:At Week 11 (optional)

Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep oxygen saturation
時間枠:At Week 11 (optional)

Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep airflow
時間枠:At Week 11 (optional)

Using sleep airflow measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep respiratory efforts
時間枠:At Week 11 (optional)

Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Snoring
時間枠:At Week 11 (optional)

Using snoring measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Changes in imagery processes
時間枠:At Day 0 and Week 11 for patients.

Using patients' EEG measures (N=60) collected with a 124-channel waveguardTMoriginal EEG cap and during 3-minute pleasant imagery suggestion audio recordings.

At Day 0 and Week 11 for patients.
Validation of the EEG methodology for the imagery processes recordings
時間枠:At Day 0

Using healthy volunteers' EEG measures (N=50) collected with a 124-channel waveguardTMoriginal EEG and during 5-minute pleasant imagery suggestion audio recordings.

At Day 0

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Chantal Berna Renella, Prof、CHUV

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年8月30日

一次修了 (実際)

2026年2月19日

研究の完了 (実際)

2026年8月15日

試験登録日

最初に提出

2023年6月2日

QC基準を満たした最初の提出物

2023年7月11日

最初の投稿 (実際)

2023年7月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • CER-VD 2023-01007

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。